Annexin A5 in Patients With Severe COVID-19 Disease
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Randomized, double-blind, placebo-controlled trial comparing 2 doses of SY-005 (recombinant
human Annexin A5) to placebo in patients with severe coronavirus 2019 disease in a single
hospital centre with 2 intensive care units
Phase:
Phase 2
Details
Lead Sponsor:
Lawson Health Research Institute
Collaborators:
London Health Sciences Foundation Ontario Ministry of Colleges and Universities